'Blood phe' presentation slideshows

Double Blind Placebo Control Trial in PKU with NeoPhe

815 views • 59 slides

ICIEM 2006

ICIEM 2006. Double Blind Placebo Control Trial in PKU with NeoPhe. Reuben Matalon 1 , Kimberlee Michals-Matalon 1 , Alberto Burlina 2 , Alesandro Burlina 2 , Marcello Giovannini 3 , Laura Fiori 3 , Elena Grechanina 4 , Peter Novikov 5 , James Grady 1 , Stephen Tyring 6 , Flemming Guttler 7

475 views • 40 slides

621 views • 39 slides

516 views • 39 slides

393 views • 39 slides

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA. 2 nd Ukraine Congress On Clinical Genetics October 2005. Ukraine Elena Grechanina Russia Peter Novikov Denmark Jytte Bieber Nielsen Leah Brammer Kirstin Ahring USA Reuben Matalon, M.D., Ph.D. Kim Matalon.

473 views • 34 slides

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA. 2 nd Ukraine Congress On Clinical Genetics October 2005. USA Reuben Matalon, M.D., Ph.D. Kim Matalon Russia Peter Novikov Denmark Jytte Bieber Nielsen Leah Brammer Ukraine Elena Grechanina. Large Neutral Amino Acids (LNAA).

785 views • 33 slides

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA

NeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA. 2 nd Ukraine Congress On Clinical Genetics October 2005. USA Reuben Matalon, M.D., Ph.D. Kim Matalon Russia Peter Novikov Denmark Jytte Bieber Nielsen Leah Brammer Ukraine Elena Grechanina. Large Neutral Amino Acids (LNAA).

467 views • 33 slides

Inborn errors of metabolism

Phenylketonuria ????? Xue Fan Gu, MD, PhD Xinhua Hospital Shanghai Jiao Tong University School of Medicine. Inborn errors of metabolism. Overview Disorders in which defects of single gene cause clinically significant blocks in metabolic pathways Many kinds of disorders Lower incidence

489 views • 21 slides

Denmark LNAA STUDY 1 tablet/kg/day

281 views • 17 slides

Phe

Hyperphenylalaninaemias (HPA) Patomechanism, types. BH 4 -dependent HPA (atypical/malignant PKU) Usually mild PKU/HPA Early CNS symptoms. Fe O 2. GTP. BH 4. BH 2. Tyr. Phe. Phenylketons FeCl 3. DOPA?DA?NA?A ??? melanin. Norm <120 ? mol/l. PAH.

348 views • 15 slides

Experience with long term use of LNAA in treatment of PKU

Experience with long term use of LNAA in treatment of PKU. Reuben Matalon 1 , Kimberlee Michals-Matalon 2 , Gita Bhatia 1 , James Grady 1 , Stephen Tyring 3 . 1 The University of Texas Medical Branch, Galveston, Texas77555. 2 University of Houston, Texas 77204,

355 views • 14 slides